The interleukin-3 receptor (CD123) is a molecule found on cells which helps transmit the signal of interleukin-3, a soluble cytokine important in the immune system.

CD123 is a biomarker for targeted therapy in certain diseases, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and acute lymphoblastic …

CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy …

Feb 10, 2014 · This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.

Emerging studies demonstrate that CD123, the interleukin 3 receptor alpha (IL-3Rα), is highly expressed in LSCs, while not normal hematopoietic stem cells (HSCs), and associates with treatment response, minimal residual disease (MRD) detection and prognosis.

Interleukin 3 receptor, alpha (low affinity) (IL3RA), also known as CD123 (C luster of D ifferentiation 123), is a human gene. [5] The protein encoded by this gene is an interleukin 3 …

Mar 20, 2025 · CD123, the alpha chain of the interleukin-3 receptor (IL-3Rα), is critical for immune regulation and hematopoiesis. It mediates cellular responses to IL-3, influencing survival, proliferation, and differentiation of various blood cell types.

Different monoclonal antibodies directed against CD123 are under evaluation as antileukemic drugs, showing promising results either for the treatment of AML minimal residual disease or of relapsing/refractory AML or BPDCN.

May 31, 2023 · In contrast, CD123 is expressed at negligibly low levels on normal hematopoietic progenitors, making it a potentially promising therapeutic target. Vibecotamab (formally XmAb14045) is a CD3-CD123 bispecific engaging antibody that has established clinical activity in relapsed/refractory AML.

Dec 2, 2021 · CD123 is a critical biomarker and promising immunotherapeutic target for children with relapsed or refractory AML, given its prevalent expression and enrichment in patients with high-risk genetic alterations and inferior clinical outcomes with conventional therapy.